AstraZeneca Plc, in the headlines for spurning takeover offers from Pfizer Inc, aims to regain prominence in oncology with compelling trial results and a splashy exhibit booth at the world's largest meeting of cancer doctors.The company is seen as No. 4 in a race to develop the first drug in a new class that fights cancer by unleashing the body's immune system, behind rivals Roche, Merck & Co and Bristol-Myers Squibb.In a presentation during the American Society of Clinical Oncology meeting in Chicago, Chief Executive Officer Pascal Soriot said AstraZeneca was progressing faster than he had expected with its cancer drug pipeline - an asset that figured prominently in its decision to rebuff Pfizer."We remain resolute in our ambition to bring these next-generation cancer medicines to patients as fast as possible," Soriot said in an investor presentation late on Monday.
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. Shares of AZN fell by 0.83% or $-0.61/share to $72.76. In the past year, the shares have traded as low as $46.87 and as high as $82.68. On average, 4994920 shares of AZN exchange hands on a given day and today's volume is recorded at 5142939.
Merck & Co., Inc. (Merck) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. Shares of MRK fell by 0.03% or $-0.02/share to $57.91. In the past year, the shares have traded as low as $44.62 and as high as $59.84. On average, 10657500 shares of MRK exchange hands on a given day and today's volume is recorded at 7078096.
Pfizer Inc. (Pfizer) is a research-based, global biopharmaceutical company. Shares of PFE fell by 0.4% or $-0.12/share to $29.59. In the past year, the shares have traded as low as $27.33 and as high as $32.96. On average, 30470700 shares of PFE exchange hands on a given day and today's volume is recorded at 24202688.
Source
